Rebecca A Marsh - JoVE Visualize

Showing results (21-30 of 124) with videos related to

Pageof 13

Sort By:

Pediatric Blood & Cancer|April 21, 2026

Outcomes of Live Virus Vaccination in Patients With Vascular Anomalies Being Treated With SirolimusSvatava Merkle, Kiersten Ricci, Kelly Blache, et al.

Journal of Human Immunity|January 29, 2026

Leniolisib reduced lymphoproliferative disease in murine autoimmune lymphoproliferative syndromeChopie Hassan, Yolanda Ponstein, Robert Hanssen, et al.

Journal of Clinical Immunology|September 19, 2020

Relationship Between Severity of T Cell Lymphopenia and Immune Dysregulation in Patients with DiGeorge Syndrome (22q11.2 Deletions and/or Related TBX1 Mutations): a USIDNET StudyDeepti R Deshpande, Yesim Y Demirdag, Rebecca A Marsh, et al.

Journal of Pediatric Hematology/Oncology|November 1, 2017

A First Report of Secondary Hemophagocytic Lymphohistiocytosis Associated With Papillary Thyroid CarcinomaConnor Wakefield, Parinda A Mehta, Sarah Corathers, et al.

Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|June 14, 2014

Reduced-intensity conditioning hematopoietic cell transplantation is an effective treatment for patients with SLAM-associated protein deficiency/X-linked lymphoproliferative disease type 1Rebecca A Marsh, Jack J Bleesing, Shanmuganathan Chandrakasan, et al.

Case Reports in Immunology|September 10, 2020

The Natural History of X-Linked Lymphoproliferative Disease (XLP1): Lessons from a Long-Term SurvivorYike Jiang, Mihail Firan, Sarada L Nandiwada, et al.

The Journal of Biological Chemistry|April 14, 2017

Nucleotide-binding oligomerization domain (NOD) signaling defects and cell death susceptibility cannot be uncoupled in X-linked inhibitor of apoptosis (XIAP)-driven inflammatory diseaseSteven M Chirieleison, Rebecca A Marsh, Prathna Kumar, et al.

Blood|March 9, 2017

Perforin and CD107a testing is superior to NK cell function testing for screening patients for genetic HLHTamar S Rubin, Kejian Zhang, Carrie Gifford, et al.

Pediatric Dermatology|September 3, 2010

Leukocyte adhesion deficiency type 1 presenting with recurrent pyoderma gangrenosum and flaccid scarringClaas H Hinze, Anne W Lucky, Kevin E Bove, et al.

Blood|December 9, 2015

Alemtuzumab levels impact acute GVHD, mixed chimerism, and lymphocyte recovery following alemtuzumab, fludarabine, and melphalan RIC HCTRebecca A Marsh, Adam Lane, Parinda A Mehta, et al.

Pageof 13

Showing results (21-30 of 124) with videos related to

Sort By:

Pageof 13

Pediatric Blood & Cancer|April 21, 2026

Outcomes of Live Virus Vaccination in Patients With Vascular Anomalies Being Treated With SirolimusSvatava Merkle, Kiersten Ricci, Kelly Blache, et al.

Journal of Human Immunity|January 29, 2026

Leniolisib reduced lymphoproliferative disease in murine autoimmune lymphoproliferative syndromeChopie Hassan, Yolanda Ponstein, Robert Hanssen, et al.

Journal of Clinical Immunology|September 19, 2020

Relationship Between Severity of T Cell Lymphopenia and Immune Dysregulation in Patients with DiGeorge Syndrome (22q11.2 Deletions and/or Related TBX1 Mutations): a USIDNET StudyDeepti R Deshpande, Yesim Y Demirdag, Rebecca A Marsh, et al.

Journal of Pediatric Hematology/Oncology|November 1, 2017

A First Report of Secondary Hemophagocytic Lymphohistiocytosis Associated With Papillary Thyroid CarcinomaConnor Wakefield, Parinda A Mehta, Sarah Corathers, et al.

Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|June 14, 2014

Reduced-intensity conditioning hematopoietic cell transplantation is an effective treatment for patients with SLAM-associated protein deficiency/X-linked lymphoproliferative disease type 1Rebecca A Marsh, Jack J Bleesing, Shanmuganathan Chandrakasan, et al.

Case Reports in Immunology|September 10, 2020

The Natural History of X-Linked Lymphoproliferative Disease (XLP1): Lessons from a Long-Term SurvivorYike Jiang, Mihail Firan, Sarada L Nandiwada, et al.

The Journal of Biological Chemistry|April 14, 2017

Nucleotide-binding oligomerization domain (NOD) signaling defects and cell death susceptibility cannot be uncoupled in X-linked inhibitor of apoptosis (XIAP)-driven inflammatory diseaseSteven M Chirieleison, Rebecca A Marsh, Prathna Kumar, et al.

Blood|March 9, 2017

Perforin and CD107a testing is superior to NK cell function testing for screening patients for genetic HLHTamar S Rubin, Kejian Zhang, Carrie Gifford, et al.

Pediatric Dermatology|September 3, 2010

Leukocyte adhesion deficiency type 1 presenting with recurrent pyoderma gangrenosum and flaccid scarringClaas H Hinze, Anne W Lucky, Kevin E Bove, et al.

Blood|December 9, 2015

Alemtuzumab levels impact acute GVHD, mixed chimerism, and lymphocyte recovery following alemtuzumab, fludarabine, and melphalan RIC HCTRebecca A Marsh, Adam Lane, Parinda A Mehta, et al.

Pageof 13